InspireMD Reports Third Quarter 2025 Financial Results

Core Insights - InspireMD, Inc. successfully launched its CGuard Prime carotid stent system in the U.S., contributing to record quarterly revenue growth [1][2] - The company reported a 39% increase in total revenue for Q3 2025, reaching $2.5 million compared to $1.8 million in Q3 2024 [3] - Despite revenue growth, the company experienced a net loss of $12.7 million for Q3 2025, compared to a net loss of $7.9 million in the same period last year [7] Business Highlights - The U.S. commercial launch of the CGuard Prime system has shown strong demand, with over 100 procedures completed across leading hospitals [9] - The company raised $58 million in gross proceeds, enhancing its ability to expand its commercial team and operations [2] Financial Performance - U.S. revenue for Q3 2025 was $497,000, while international revenue was $2.0 million, driven by the CGuard Prime launch and increased market penetration [3] - Gross profit for Q3 2025 was $864,000, an increase from $414,000 in Q3 2024, attributed to higher margin revenue from the U.S. launch [4] - Total operating expenses rose by 57% to $13.9 million in Q3 2025, primarily due to increased headcount and infrastructure costs [5] Financial Metrics - Financial income for Q3 2025 decreased by 40% to $343,000 compared to $572,000 in Q3 2024 [6] - Cash and cash equivalents as of September 30, 2025, were $63.4 million, up from $34.6 million at the end of 2024 [7] - The weighted average number of ordinary shares used in computing net loss per share was 73,466,501 for Q3 2025 [14]